In the first of a new three-part series, Graham Woodward, Chief Medical Officer at Releaf, sat down with Business of Cannabis to discuss what it takes to scale a medical cannabis clinic from three patients to tens of thousands in just two years.
Curaleaf Laboratories and Vericura today announced an agreement to strengthen the manufacturing and distribution of medical cannabis products across the United Kingdom.
By Ben Stevens, with additional reporting by Nicole Farah, Managing Director of Americana Communications.
Pressure is piling on the UK’s Advisory Council on the Misuse of Drugs (ACMD) to publish its highly anticipated review of the country’s medical cannabis framework.
In the UK, cannabis remains a Class B drug under the Misuse of Drugs Act 1971, meaning the possession, supply and cultivation for recreational purposes are all criminal offences carrying significant potential sentences.
James Duckenfield, CEO of Glass Pharms®, explains why we may be underestimating the pharmaceutical potential of cannabis, and how research, formulation and more controlled delivery could help realise it.
Northern Leaf, the Jersey-based medical cannabis cultivator, looked all but certain to follow in the footsteps of Curaleaf, Aurora and Tilray to become the British Isles’ very own international cannabis superstar.
Earlier this month, we published new data from two separate Freedom of Information (FOI) requests providing the most complete and up-to-date picture yet of the UK’s medical cannabis market.
As Aurora faces down an unsolicited takeover bid from one of the world’s largest cannabis companies, it has continued to expand its reach in what it sees as the markets of the near future.
